At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the recent progress in understanding clinically relevant genomic alterations in kidney cancer. Genomic profiling of collecting duct carcinomas, a rare kidney cancer subtype, revealed a high frequency of NF2 genomic alterations, which may represent opportunities for the application of targeted therapies.
Molecular characterisation of kidney cancer and opportunities for targeted therapies
10th July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now